Market: median 1d +0.0% · breadth 14.9% advancing across 188 names
Data as of — announcements 2026-07-14 · flow 2026-07-09 · prices 2026-07-13
New today: AIS, GA8, KLI, MRD, MSB. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (5)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
AIS delivered FY26 production within guidance (42.1kt Cu-eq) with copper up 19% YoY at Tritton despite Q2 geotechnical delays, and fortified balance sheet ($202.3m cash+receivables) to fund near-term growth. Stock flat pre-announcement despite operational delivery, suggesting guidance miss on copper and no material catalysts priced in ahead of FY27 guidance release.
Materiality: Cash position ($202.3m ≈ 35% of $576m market cap) provides 1.5–2yr runway for Constellation development at estimated burn; copper miss (23kt vs 24–29kt guidance midpoint) is ~4% below, immaterial to valuation narrative but indicators execution headwinds.
Priced in? No run-up (flat 5d, -10% over 20d); results were in-line but undershoots on copper and lack of forward surprise suggest market was not anticipating upside; FY27 guidance due imminently may reset sentiment.
GA8 · $43M — Further Standout Intercepts at Mt Stirling Well
GoldArc's Mt Stirling Well grade control results confirm systematic high-grade quartz-vein shoots (peak 31.0 g/t Au) consistent with the 2.3 g/t resource estimate, strengthening ore body definition ahead of MDCP approval. Four successive batches of repeatable intercepts and partner-funded drilling (fully funded by BMLV, 50/50 NPS) de-risk the Leonora North development path toward production.
💰Mt Stirling Well best intercept: 1m @ 31.0 g/t Au · Mt Stirling Well resource: 198,000t @ 2.3 g/t Au (15,000oz) · Grade control program completion: ~74% (25,292m of 34,000m) · Mt Stirling Well high-grade shoots: Multiple intercepts >6 g/t Au, four consecutive batches confirmed
Materiality: Grade control results inform mine planning and MDCP approval pathway; drilling is 74% complete and fully partner-funded, reducing capital exposure. At $43m market cap, successful MDCP approval and transition to development would be transformative, though current metrics alone insufficient to quantify impact.
Priced in? Stock +11% over 5d into announcement; modest pre-announcement run-up suggests some anticipation, but standout 31.0 g/t intercept and confirmation of systematic high-grade shoots likely new/incremental.
🏔 near TAM.AX ($136M — 3.13× subject cap) · near GMD.AX ($6.7B major in district)
high-confidence read, materiality quantified
KLI — Killi Targets Rapid Resource Growth with Aggressive Drilling
Killi has secured government approvals and is finalizing drilling contracts to commence a 20,000m campaign aimed at expanding its 110Mt Lodestone magnetite resource along a 25km system and testing parallel zones. The project targets a high-purity DR-grade concentrate premium market, supported by tier-one WA infrastructure and recent $15m placement.
Materiality: Raise (~$15m) represents ~36% of current market cap; drilling campaign is foundational to converting inferred resource into mineable ore body and establishing development pathway.
Priced in? Stock down 25% over 20d and 10% over 5d into announcement; market may be pricing execution risk despite positive drilling news.
Phase 1 re-assay of Block 2 confirms scandium mineralisation extends beyond current resource boundaries in all directions, with grades 30–47% above the existing 86.9 ppm average, validating a larger district-wide critical minerals system. Low-cost pathway to material resource expansion via historical drill pulp re-assaying, with Phase 2 (~2,000 samples) underway.
Materiality: Low-cost re-assay upside on a $32m market cap; no new capex disclosed. Expansion potential material if Phase 2 confirms similar grade/thickness trends, but insufficient cash data to quantify runway.
Priced in? Stock +5% over 5d into announcement, but −8% over 20d prior; modest institutional/retail accumulation ($5k/$9.4k/day); result appears partially anticipated but not fully priced.
MSB has enrolled the full 300-patient cohort for its pivotal Phase 3 CLBP trial (rexlemestrocel-L), confirming the trial is adequately powered to replicate prior Phase 3 endpoint success; FDA RMAT designation and priority-review eligibility position the program for accelerated approval pathway if efficacy holds.
💰Patients enrolled: 300 (target achieved) · Primary endpoint: Pain reduction at 12 months vs. sham · Market opportunity (peak revenue): >US$10 billion · US CLBP prevalence: 7 million patients
Materiality: Enrollment completion de-risks pivotal trial execution on a ~$3B market-cap company; blockbuster revenue potential (>US$10B peak) suggests material upside if Phase 3 succeeds, though 18-month readout delay limits near-term catalysts.
Priced in? Stock +20% over 20d and +13% over 5d ahead of announcement; enrollment milestone was previously telegraphed, suggesting market was pricing in eventual completion; no new efficacy data released.
ILT — ILT commences drilling to test Herberton regional targets · quantified but moderate — skim
LNQ — High Grade 5.36% CuEq Intersection at Monza · quantified but moderate — skim
RCM — Update to Release of 22 May 2026-Drilling Underway at Webbs · quantified but moderate — skim
RDS — RDS to Advance Saturn Cu-Ni-Co-PGE and PGE Reef Project · quantified but moderate — skim
SLM — Drilling Commenced At Mandacaru Lithium Project, Brazil · quantified but moderate — skim
Broker tape — caveats
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.